ASX:OSLPharmaceuticals, Biotechnology & Life SciencesLife Sciences Tools & Services
Oncosil Medical Ltd
$1.155
+$0.005 (+0.43%)
Day Range
$1.140 – $1.175
52 Week Range
$0.370 – $2.078
Volume
34.63K
Avg Volume (10D)
263.64K
Market Cap
$35.68M
Price Chart
OHLC · volume · moving averages
$1.155+$0.475 (+69.85%)over 6M
Hi$1.640Lo$0.370Avg Vol160.4K
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$1.140
Previous Close
$1.150
Day High
$1.175
Day Low
$1.140
52 Week High
$2.078
52 Week Low
$0.370
Valuation
Fundamental multiples
Market Cap
35.68M
Shares Outstanding
30.89M
Price to Book
5.67
Trading Activity
Volume & order book
Volume
34.63K
Value Traded
39.96K
Bid
$1.155 × 9,839
Ask
$1.165 × 900
Performance
Returns across timeframes
1 Day
-4.17%
5 Day
-13.53%
13 Week
194.87%
52 Week
-0.72%
YTD
19.24%
Technical Indicators
Momentum & moving averages
RSI (14)
48.59
50-Day SMA
$1.054
200-Day SMA
$0.799
— From the desk
Latest News
Biotechnology
OncoSil Medical Receives FDA Exemption Approval for Targeted Radiation Device
OncoSil wins FDA humanitarian device exemption for dCCA, unlocking US market ~1,000 patients/year and $80m TAM; launch set for H2 2027.
Biotechnology
OncoSil Medical Completes Manufacturing Validation of Pancreatic Cancer Treatment
OncoSil completes three manufacturing validation cycles for pancreatic cancer brachytherapy device, de-risking scale-up; regulatory review ongoing; H2 prod.
Biotechnology
OncoSil FDA HDE Application Reaches Final Review as TRIPP-FFX Hits Endpoints
OncoSil's FDA HDE for distal cholangiocarcinoma advances to final review as TRIPP-FFX hits endpoints in pancreatic cancer; ASX: OSL.
Biotechnology
OncoSil Medical Secures TGA Approval in Australia for Pancreatic Cancer Device
OncoSil Medical wins TGA approval for OncoSil device to treat unresectable LAPC; ARTG-listed, enabling Australian launch as manufacturing scales up.